Skip to main content
. 2018 Dec 19;9:5378. doi: 10.1038/s41467-018-07620-0

Fig. 2.

Fig. 2

SRPK1 inhibition has no lasting effects on normal hematopoiesis. a Quantitation of LSK (Lin/Sca1+/Kit+) and HSC (LSK/CD150+/CD34) compartments in bone marrow from WT mice three weeks after treatment with vehicle or SPHINX31 (2 mg/kg). b Colony-forming assay of WT lineage negative (Lin−) HSPCs during (plating 1) and after (platings 2 & 3) treatment with 3 μM SPHINX31 (mean ± s.d., n = 3). c Colony-forming efficiency of CD34+ human cord blood cells (n = 4) in the presence of 1.5, 3, or 6 uM SPHINX31 (mean ± s.d., n = 4). These changes are not significant at the 95% confidence level according to one-way Anova on repeated measures. Error bars refer to variation across 4 different individuals (blue circle, brown square, red triangle, and green triangle). d Colony-forming efficiency of primary human MLL-X AML cells treated with 1.5, 3, or 6 μM SPHINX31 or 1 μM iBET-151 (mean ± s.d., n = 3 technical replicates). e Colony-forming efficiency of primary human MLL-WT AML cells treated with 1.5, 3, or 6 μM SPHINX31 or 1 μM iBET-151 (mean ± s.d., n = 3 technical replicates). HSC, hematopoietic stem cells; CFU, colony forming units; n.s., not significant; *p < 0.001 (t-test)